(MENAFN- EIN Presswire)
Duchenne Muscular Dystrophy market Forecast
DelveInsight's Duchenne Muscular Dystrophy Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.
LAS VEGAS, NEVADA, UNITED STATES, June 11, 2024 /EINPresswire / -- DelveInsight's“Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Duchenne Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Duchenne Muscular Dystrophy Market Forecast
Some of the key facts of the Duchenne Muscular Dystrophy Market Report:
The Duchenne Muscular Dystrophy market size was valued approximately USD 2,150 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In January 2024, Santhera Pharmaceuticals unveiled the launch of AGAMREE (vamorolone) in Germany for the treatment of Duchenne muscular dystrophy (DMD) patients aged four years and older. This marks Santhera Pharmaceuticals' official entry into the commercial phase of its biopharmaceutical endeavors.
In 2023, the United States had the highest prevalence of Duchenne muscular dystrophy (DMD) among the 7MM countries, with approximately 17,200 cases, projected to increase at a favorable compound annual growth rate (CAGR).
In 2023, there were approximately 13,800 cases of large mutation and 3,400 cases of small mutation in the United States. Additionally, point mutation accounted for around 1,700 cases during the same year. It is anticipated that these cases will rise over the study period from 2024 to 2034 alongside the increase in prevalence.
In 2023, there were approximately 8,200 cases of ambulatory and 8,900 cases of non-ambulatory individuals in the US. These numbers are anticipated to rise by the year 2034.
Key Duchenne Muscular Dystrophy Companies: Taiho Pharma, Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others
Key Duchenne Muscular Dystrophy Therapies: TAS205 (pizuglanstat), Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others
The Duchenne Muscular Dystrophy epidemiology based on gender analyzed that Duchenne Muscular Dystrophy rarely affects females
The Duchenne Muscular Dystrophy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.
Duchenne Muscular Dystrophy Overview
Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects boys, typically becoming evident in early childhood between the ages of 3 and 5. DMD is caused by mutations in the dystrophin gene located on the X chromosome, leading to the absence or deficiency of dystrophin, a protein essential for maintaining muscle cell structure and function.
Get a Free sample for the Duchenne Muscular Dystrophy Market Forecast, Size & Share Analysis Report:
Duchenne Muscular Dystrophy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Duchenne Muscular Dystrophy Epidemiology Segmentation:
The Duchenne Muscular Dystrophy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Duchenne Muscular Dystrophy
Prevalent Cases of Duchenne Muscular Dystrophy by severity
Gender-specific Prevalence of Duchenne Muscular Dystrophy
Diagnosed Cases of Episodic and Chronic Duchenne Muscular Dystrophy
Download the report to understand which factors are driving Duchenne Muscular Dystrophy epidemiology trends @ Duchenne Muscular Dystrophy Epidemiology Forecast
Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Duchenne Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Duchenne Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Duchenne Muscular Dystrophy Therapies and Key Companies
TAS205 (pizuglanstat): Taiho Pharma
Givinostat (ITF2357): Italfarmaco
ATL1102: Antisense Therapeutics
SRP-9001: Sarepta Therapeutics
Vamorolone: Santhera Pharmaceuticals/ReveraGen Biopharma
PF06939926: Pfizer
Pamrevlumab: FibroGen
CAP-1002: Capricor Therapeutics
Pamrevlumab: Fibrogen
Delandistrogene moxeparvovec: Roche/Sarepta Therapeutics
EDG 5506: Edgewise Therapeutics
WVE N531: Wave Life Sciences Ltd
PGN EDO51: PepGen
UX810: Ultragenyx Pharmaceutical
Duchenne Muscular Dystrophy Market Strengths
Glucocorticosteroids, which is the mainstay treatment option results in various adverse side effects, whereas the newer corticosteroids such as EMFLAZA is not cost effective in the United States.
No cure or disease reversible therapy is available for non-ambulant DMD patients.
Duchenne Muscular Dystrophy Market Opportunities
Ongoing research in gene therapy and genetic technologies presents opportunities for developing targeted and personalized treatments for DMD.
Wider commercial opportunity for therapies such as Capricor's CAP-1002 and Antisense's ATL1102, which are specifically focusing on improving upper limb functions in DMD patients and are targeting a much larger patient segments.
Scope of the Duchenne Muscular Dystrophy Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Duchenne Muscular Dystrophy Companies: Taiho Pharma, Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others
Key Duchenne Muscular Dystrophy Therapies: TAS205 (pizuglanstat), Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others
Duchenne Muscular Dystrophy Therapeutic Assessment: Duchenne Muscular Dystrophy current marketed and Duchenne Muscular Dystrophy emerging therapies
Duchenne Muscular Dystrophy Market Dynamics: Duchenne Muscular Dystrophy market drivers and Duchenne Muscular Dystrophy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Duchenne Muscular Dystrophy Unmet Needs, KOL's views, Analyst's views, Duchenne Muscular Dystrophy Market Access and Reimbursement
To know more about Duchenne Muscular Dystrophy companies working in the treatment market, visit @ Duchenne Muscular Dystrophy Clinical Trials and Therapeutic Assessment
Table of Contents
1. Duchenne Muscular Dystrophy Market Report Introduction
2. Executive Summary for Duchenne Muscular Dystrophy
3. SWOT analysis of Duchenne Muscular Dystrophy
4. Duchenne Muscular Dystrophy Patient Share (%) Overview at a Glance
5. Duchenne Muscular Dystrophy Market Overview at a Glance
6. Duchenne Muscular Dystrophy Disease Background and Overview
7. Duchenne Muscular Dystrophy Epidemiology and Patient Population
8. Country-Specific Patient Population of Duchenne Muscular Dystrophy
9. Duchenne Muscular Dystrophy Current Treatment and Medical Practices
10. Duchenne Muscular Dystrophy Unmet Needs
11. Duchenne Muscular Dystrophy Emerging Therapies
12. Duchenne Muscular Dystrophy Market Outlook
13. Country-Wise Duchenne Muscular Dystrophy Market Analysis (2020–2034)
14. Duchenne Muscular Dystrophy Market Access and Reimbursement of Therapies
15. Duchenne Muscular Dystrophy Market Drivers
16. Duchenne Muscular Dystrophy Market Barriers
17. Duchenne Muscular Dystrophy Appendix
18. Duchenne Muscular Dystrophy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here
MENAFN10062024003118003196ID1108317362